Selasa, 15 April 2025

A Rare Moment of Alignment in Washington

Shield

AN OXFORD CLUB PUBLICATION

Loyal reader since October 2020

Liberty Through Wealth

View in browser

EDITOR'S NOTE

There's a seismic shift coming to the healthcare space - and savvy investors need to be watching it closely.

On April 30, a Medicare decision linked to the H.R. 2407 bill in Congress could pave the way for nationwide coverage of a game-changing cancer screening test.

The real story? A $1.1 billion microcap firm is already steps ahead - with exclusive patents, a vast DNA database, and a direct partnership with Medicare.

If coverage is approved, this company could see explosive growth, becoming a leader in early cancer detection and delivering extraordinary returns to early investors.

Trust me, you'll want to check out this opportunity before the mainstream press catches on.

Click here now to view the urgent briefing before April 30.

- Nicole Labra, Senior Managing Editor

THE SHORTEST WAY TO A RICH LIFE

A Rare Moment of Alignment in Washington

Rachel Gearhart, Publisher, The Oxford Club

Rachel Gearhart

It's not often that Washington D.C., Wall Street, and medical innovation all align at the same time.

But that's exactly what's happening right now... and savvy investors who recognize this rare setup could experience one of the most lucrative opportunities of the decade.

It all centers around a groundbreaking new bill quietly advancing through Congress, called H.R. 2407.

At first glance, it looks like a run-of-the-mill Medicare policy update. But if you dig deeper, you'll see something noteworthy...

A legislative green light that could give more than 60 million seniors access to a revolutionary early cancer detection test.

This test doesn't require invasive scans or procedures. A simple blood draw that could detect cancer at Stage 1, when treatment success rates skyrocket.

For families across America, this could be life saving.

But for early investors who know where to look, it could also be a once-in-a-generation chance to profit from the biggest medical breakthrough of 2025.

SPONSORED

Trump's "Document 20" Revealed:
Smart Americans Could Get Rich

Trump's 'Document 20'
 

Details on a special dossier written by President Trump himself have just been revealed.

One top investment expert expects this explosive document could soon send the market into a Second Trump Stockwave.

The last time this happened, stocks surged as high as 3,480% in 4 years.

See if stocks could soar as much as 1,000%+ if history repeats itself.

The Stock Hiding Behind the Headline

Chief Investment Strategist Alexander Green has been tracking this story for months...

While most are focused on the bill itself, Alex has zeroed in on a single company he believes is positioned to benefit the most.

This company is small - sporting a $1.1 billion market cap. But its potential is enormous.

This company is already...

  • Running a 50,000-patient trial in collaboration with Medicare
  • Sitting on what may be the world's largest cancer DNA database
  • And protecting its test with a suite of patents on proprietary "Stage 1" detection tech.

Before the bill even passes, this company could secure exclusive access to the Medicare market through a rarely used policy shortcut called "coverage with evidence development."

That would make it the de facto leader in cancer screening for America's seniors - a market that could be worth billions in annual revenue.

And based on our research, that could send the stock soaring by 50X or more in the years ahead.

SPONSORED

Five Dividend Stocks to Buy Now (FREE INSIDE)

Marc Lichtenfeld - income expert and author of Get Rich with Dividends - is giving away his Ultimate Dividend Package...

Completely free of charge!

Seriously, no credit card required.

Inside, you'll get the names and ticker symbols of his TOP FIVE dividend stocks right now, including...

  • An "A"-rated, ultra-safe dividend stock with a huge 8% yield
  • Three of Marc's favorite "Extreme Dividend" stocks, which could supercharge your income
  • And finally, his No. 1 dividend stock for a LIFETIME of income.

Click here before the download link expires.

Why Timing Is Everything

This is one of those rare setups where policy, innovation, and investor timing all converge.

Congress is expected to move forward with H.R. 2407 in the coming weeks. When it does, headlines will spread. Analysts will scramble. And institutional money will likely rush into this tiny stock.

By then, the biggest gains will be gone.

That's why we've published an urgent investor briefing detailing everything you need to know about the test, the bill, and the small cap company that could soon dominate this high-stakes corner of the healthcare world.

As Alex said in a recent note to Members...

"Most investors will see a Medicare bill. But if you look closer, you'll see a potential 5,000% profit window opening up - and possibly closing just as fast."

The early data is compelling. The timing is urgent. And if this company's tech becomes the Medicare standard, early investors could look back on this moment as the decision that changed everything.

Click here now to watch our exclusive briefing and get the name of the company before the story breaks.

To your health and wealth,

Rachel

Trump Is About to Change Everything

BUILD AND PROTECT YOUR WEALTH

SPONSORED

Before he died, Warren Buffett's investing partner of 60 years, Charlie Munger, issued one final warning...

"What everybody has learned is that everybody needs some significant participation in the 12 companies that do better than everybody else. You need two or three of them, at least. Because a significant percentage of all the gains that come to all common stockholders combined is going to come from a few of these supercompetitors."

What was Charlie Munger's Final Investment?
Click here for my full investigation...

Tidak ada komentar:

Posting Komentar